Gilead exercised its option to exclusively license Kymera Therapeutics’ KT-200, an oral CDK2 molecular glue degrader candidate, according to the companies. The move expands Gilead’s oncology pipeline with a next-step program expected to enter IND-enabling work, with the goal of filing for clinical testing. Kymera’s KT-200 is differentiated from CDK2 inhibitors by using a molecular-glue mechanism designed to drive degradation rather than enzymatic blockade. That framing is aimed at addressing selectivity and toxicity issues that have historically complicated CDK pathway targeting. Kymera had already advanced the program through preclinical discovery and selection of a development candidate, and the license adds a new development lane for KT-200 as competitors push into CDK2 inhibition across early clinical stages. Gilead’s option decision also signals that the broader molecular-glue strategy remains active for Big Pharma as it looks beyond single-mechanism small molecules. For investors and competitors, the licensing emphasizes how “option-to-license” pathways can rapidly translate preclinical differentiation into partnered clinical programs, particularly when targets are crowded and differentiation depends on tolerability and mechanism-of-action precision.